StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson vELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide reported growth YoY (%) (%)

Form 8-K EX-99.2 Segment Sales Schedule

QuarterlyAnnual
Latest, Q4 2020
-15.2%
Period ended Jan 3, 2021
Change on a year earlier
+39.4 pts
-54.6% in Q4 2019
History
13 quarters
Since Q4 2017
Sources
13
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide reported growth YoY (%) (%)Year on yearSource
Q4 2020Jan 3, 2021-15.2%+39.4 ptsForm 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗
Q3 2020Sep 27, 2020-30.1%+14.7 ptsForm 8-K (a2020q3exhibit991.htm, filed 2020-10-13) ↗
Q2 2020Jun 28, 2020-56.1%-36.0 ptsForm 8-K (a2020q2exhibit991.htm, filed 2020-07-16) ↗
Q1 2020Mar 29, 2020-59.0%-43.0 ptsForm 8-K (a2020q1exhibit991.htm, filed 2020-04-14) ↗
Q4 2019Dec 29, 2019-54.6%-47.6 ptsForm 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗
Q3 2019Sep 29, 2019-44.8%-44.1 ptsForm 8-K (a2019q3exhibit991.htm, filed 2019-10-15) ↗
Q2 2019Jun 30, 2019-20.1%-16.7 ptsForm 8-K (a2019q2exhibit9915.htm, filed 2019-07-16) ↗
Q1 2019Mar 31, 2019-16.0%-27.8 ptsForm 8-K (a2019q1exhibit9915.htm, filed 2019-04-16) ↗
Q4 2018Dec 30, 2018-7.0%-5.9 ptsForm 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗
Q3 2018Sep 30, 2018-0.7%–Form 8-K (a8k2018q3exhibit9915.htm, filed 2018-10-16) ↗
Q2 2018Jul 1, 2018-3.4%–Form 8-K (a8k2018q2exhibit9915.htm, filed 2018-07-17) ↗
Q1 2018Apr 1, 201811.8%–Form 8-K (a8k2018q1exhibit9915.htm, filed 2018-04-17) ↗
Q4 2017Dec 31, 2017-1.1%–Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗

Cite this data

StockData. (2026). Johnson & Johnson VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide reported growth YoY (%) (%), quarterly Q4 2017–Q4 2020 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_velcade_rep_yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.